Janpix Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Janpix Ltd. - overview
Established
2013
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Janpix Ltd. is a biotechnology company focused on developing innovative therapies for cancer treatment through advanced drug discovery and development processes. Founded in 2013, Janpix Ltd. is based in Cambridge, US.
The company specializes in creating targeted cancer therapies, and it has completed 2 deals, with the most recent deal occurring on October 7, 2020. Janpix raised USD 10. 00 mn in Series B funding led by Medicxi Ventures. The CEO is Pierre Cortes, and the company has benefited from the experience of its founders, Anthony Casalena and Roman Fleck.
Janpix Ltd. develops cutting-edge therapies aimed at treating various forms of cancer. The company focuses on creating novel drug candidates that leverage advanced scientific techniques to enhance therapeutic efficacy and patient outcomes. Their products target specific cancer pathways, contributing to personalized medicine approaches.
Janpix Ltd. operates on a model that includes funding through equity investments, allowing for the support of its research and development activities. The company’s recent funding round of USD 10. 00 mn will facilitate the advancement of its cancer therapies and broaden its research capabilities.
With the recent funding of USD 10. 00 mn from its Series B round completed in October 2020, Janpix Ltd. aims to expedite the development of new cancer therapies. The company plans to expand its research efforts in specific cancer indications and intends to enhance its portfolio with additional novel drug candidates targeted for release within the next two years.
Moreover, Janpix is looking to expand its market reach beyond the US into Europe and Asia by 2023.
Current Investors
Medicxi
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.janpix.squarespace.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Janpix Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.